ORIGINAL ARTICLE |
|
Year : 2014 | Volume
: 8
| Issue : 2 | Page : 108-114 |
|
Role of serum proadrenomedullin in assessment of the severity and outcome of hospitalized healthcare-associated pneumonia patients
Amany Shaker1, Doaa Mostafa Gad1, Sameh Embarak MD 1, Hany A Labib2
1 Department of Chest, Faculty of Medicine, Zagazig University, Zagazig, Egypt 2 Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Correspondence Address:
Sameh Embarak Department of Chest, Faculty of Medicine, Zagazig University, Zagazig, 44511 Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/1687-8426.145702
|
|
Background Clinical judgment of healthcare-associated pneumonia (HCAP) represents a major concern as these fragile patients have an unusual presentation that frequently misleads severity assessment and results in poor clinical outcome. The aim of this study was to evaluate the role of proadrenomedullin (proADM) in predicting disease severity and outcome in HCAP patients in comparison with community-acquired pneumonia (CAP) patients.
Patients and methods Thirty-one HCAP patients and twenty-five CAP patients were enrolled in this study. Measurement of serum proADM level was performed in the first 24-h of admission. Assessment of severity was carried out using the CURB-65 scoring system. Finally, the outcome of the patients was assessed.
Results Serum proADM level was higher in HCAP patients than that in CAP patients, this difference was statistically significant. Also, serum proADM level increased significantly with increasing severity of HCAP patients guided by CURB-65, with a cut-off value of more than 1.8 nmol/l, with a sensitivity of 91.7%, a specificity of 95%, a positive predictive value of 91.7%, and a negative predictive value of 95%. However, a higher value (>2.9 nmol/l) was detected in HCAP patients who died, with high sensitivity and negative predictive value (100%) and low specificity (42.3%) and positive predictive value (25%).
Conclusion The use of proADM as a novel biomarker enhances the performance of the CURB-65 scoring system for risk stratification of HCAP patients. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|